| HOME >> BIOLOGY >> TECHNOLOGY |
Presenters include David M. Mott from MedImmune Inc., Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company, Federico Goodsaid, Ph.D from the
FDA, and Mark Ratner from FDC_Windhover
WESTBOROUGH, Mass., May 7 /PRNewswire/ -- IBC Life Sciences announced the keynote line up for the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress, to take place August 4-7, 2008 in Boston, MA. The keynote presentations will include speakers David M. Mott from MedImmune Inc. and Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company. Keynote panel discussions this year will be led by Federico Goodsaid, Ph.D from the FDA, and Mark Ratner from FDC Windhover.
The two individual keynote speakers will discuss the scientific and business strategies that are necessary to move to clinical POC quickly. Keynote panel discussions will approach the more "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry. Presentations include:
4:20 PM, Tuesday, August 5:
Keynote speaker David M. Mott, Chief Executive Officer and President, MedImmune, Inc. will present "Risk-Taking & Innovation in Biotechnology: The MedImmune Success Story."
5:00 PM, Tuesday, August 5:
Keynote panel discussion "Biomarker Qualification in Drug Development: A Regulatory/Industry Discussion" will be led by Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.
11:20 AM, Wednesday, August 6:
Keynote speaker Elliott Sigal, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Research & Development, Bristol-Myers Squibb Company will discuss "BioPharma of the Future: Blending the Best to Create the Next."
12:00 PM, Wednesday, August 6:
Keynote panel discussion "Leading in a Sea of
'/>"/>
| SOURCE IBC Life Sciences Copyright©2008 PR Newswire. All rights reserved |